Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 10/20 | 0.41 |
| ▸ | MLNR | O43193 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25987495 | 0.93 | CHRM3 (0.44) | ATMCHRM3MLNRCHRM2CHRM1 | |
| SCHEMBL9906131 | 0.89 | ATM (0.49) | ATMCHRM3CHRM2 | |
| SCHEMBL17465721 | 0.82 | ATM (0.44) | ATMCHRM3CHRM2CHRM1HRH3 | |
| SCHEMBL14534160 | 0.82 | CHRM3 (0.55) | ATMCHRM3MLNRCHRM2CHRM1 | |
| SCHEMBL28947431 | 0.82 | ATM (0.44) | ATMCHRM3MLNRCHRM2CHRM1 | |
| SCHEMBL17886845 | 0.81 | CYP19A1 (0.41) | ATMCHRM3CYP19A1 | |
| SCHEMBL2928686 | 0.81 | ATM (0.67) | ATMCHRM3CHRM2CHRM1HRH3 | |
| SCHEMBL25987491 | 0.80 | ATM (0.66) | ATMCHRM3CHRM2CHRM1 | |
| SCHEMBL15823587 | 0.79 | EPHX2 (0.41) | CHRM3 | |
| SCHEMBL19504740 | 0.79 | ATM (0.42) | ATMCHRM3CHRM1KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230256106-A1 | DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF | COVAL BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230256106-A1 | DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF | COVAL BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-8785633-B2 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130267706-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-10-10 | — | — | US | disclosed |
| US-8338424-B2 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20120219509-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8198304-B2 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20110319448-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-8039489-B2 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20110201583-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-7960385-B2 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090069335-A1 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267706-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM1 | ATM 2759/4885CHRM3 1/4885MLNR 315/4885 |
| US-20230256106-A1 | DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF | TIE1, TEK, KDR | ATM 3380/4885CHRM3 4650/4885MLNR 2046/4885 |
| US-20110201583-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM1 | ATM 2759/4885CHRM3 1/4885MLNR 315/4885 |
| US-20110319448-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM1 | ATM 2759/4885CHRM3 1/4885MLNR 315/4885 |
| US-20120219509-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM1 | ATM 2759/4885CHRM3 1/4885MLNR 315/4885 |
| US-20090069335-A1 | Guanidine-containing compounds useful as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM1 | ATM 2759/4885CHRM3 1/4885MLNR 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.